ClinicalTrials.gg
WithdrawnNCT04325932Updated Mar 30, 2020

Study of Urinary Kallikrein to Enhance Collateral Circulation in Symptomatic Intracranial Atherosclerosis

A Phase 4 interventional study of Urinary Kallikrein in Intracranial Arteriosclerosis, Collateral Circulation and Anterior Cerebral Circulation Infarction, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University. Withdrawn at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-30.

Sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University · Phase 4, Interventional, and Basic science

From the registry’s dates

  • Registered 1 year 9 months after the study started (first participant enrolled Jan 2016, registered Oct 2017).
Phase
Phase 4
Study type
Interventional
Enrollment
0
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to determine whether Urinary Kallikrein has an additional effect on enhancing collateral circulation in symptomatic intracranial atherosclerotic patients under clopidogrel and aspirin dual antiplatelet therapy.

02

Conditions studied

  • Intracranial Arteriosclerosis
  • Collateral Circulation
  • Anterior Cerebral Circulation Infarction
03

In context

Intracranial Arteriosclerosis

102 studies on the registry are indexed under Intracranial Arteriosclerosis; 48 are open to participants now.

Browse Intracranial Arteriosclerosis studies →

Lead sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University is the lead sponsor of 1,047 studies on the registry; 502 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Acute ischemic stroke or within 72 hours;
  2. Intracranial ICA, MCA M1 segment stenosis (>70%)

Exclusion criteria

Exclusion Criteria:

  1. >70% Stenosis in an intracranial artery other than the culprit artery.
  2. >50% Stenosis of an extracranial carotid or vertebral artery on the ipsilateral side.
  3. Perforator strokes based on MRI.
  4. Non-atherosclerotic lesion, for example, moyamoya disease, vascular inflammatory disease due to infection, autoimmunity diseases, developmental or genetic abnormalities, for example, fibromuscular dysplasia, sickle-cell anaemia, suspected vasospasm.
  5. Potential cardiac embolism as cause.
  6. Intracranial haemorrhage within 6 weeks.
  7. Concomitant intracranial tumour, aneurysm or arteriovenous malformation.
  8. Known for heparin, aspirin, clopidogrel or contrast.
  9. \<10 g/dL, blood count \<100 000, international normalisation ratio >1.5, or other uncorrectable coagulopathies.Impaired liver function ( or glutamic oxalacetic transaminase ≥ 3×) or renal function (serum creatinie ≥ 1.5mg/dl);
  10. A baseline modified Rankin Score of ≥3.
  11. of \<1 year due to the concomitant illness.
  12. Pregnant or lactating women.
  13. long-term statins users.
  14. History of mental instability or dementia.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 4
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Urinary Kallikrein group

    Urinary Kallikrein for injection, 0.15PNA IU,qd, for 2 weeks, administered within 96 hours after TIA or acute ischemic stroke, with basic therapies like dual antiplatelet therapy, blood pressure-lowering therapy and lipid-lowering therapy.

    Drug: Urinary Kallikrein

  • No intervention
    control group

    with basic therapies like dual antiplatelet therapy, blood pressure-lowering therapy and lipid-lowering therapy.

Interventions

  • DrugUrinary Kallikrein

    Also known as: Urinary Kallidinogenase

06

What researchers measure

Primary outcomes

  1. the percentage of patients with modified Rankin Score (mRS) equivalent to or less than 2

    Time frame: 3 months

Secondary outcomes

  1. rLMC scale of Collateral circulation

    We use regional leptomeningeal score(rLMC) score to measure collateral circulation.rLMC score is based on scoring pial and lenticulostriate arteries in 6 ASPECTS regions(M1-6) plus anterior cerebral artery region and basal ganglia. Pial arteries in the Sylvian sulcus are scored 0,2, or 4.

    Time frame: 2 weeks, 1 month

  2. NIHSS score

    Time frame: 2 weeks, 1month

  3. Hemorrhageic complications

    Hemorrhageic complications including intracranial, digestive tract

    Time frame: 2 weeks, 1 month, 3 months, 6 months

  4. New stroke or transient ischemic attack(TIA)

    Time frame: 6 months

07

Study locations

1 site
  • The second affiliated hospital of Zhejiang University
    Hangzhou, Zhejiang 310000, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2016 to primary completion in May 2019, 40 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2017
First posted
Mar 30, 2020
StartActual
Jan 2016
Primary completionActual
May 2019
CompletionActual
Jul 2019
Last update
Mar 30, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04325932
Responsible party
Sponsor
First posted
Mar 30, 2020
Start date
Jan 2016
Primary completion
May 2019
Completion
Jul 2019
Last update
Mar 30, 2020

Study contacts

Min Lou, Ph.D,M.D.
study chair · second affiliated hospital of Zhejiang University, school of medicine

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in May 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion